Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefuroxime and Piperacillin Concentrations in the Biliary System
2021-002629-95Phase 4Completed
- Sponsor
- Sygehus Lillebælt
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of cefuroxime and piperacillin in acute cholecystitis, cholangiolitis, chronic cholecystitis and 2 more (2 arms), sponsored by Sygehus Lillebælt. Primary endpoint: Time above the minimal inhibitory concentration in bile and plasma. Started Jun 2022; status: completed.
02
Drugs
cefuroximepiperacillin
03
Conditions
acute cholecystitischolangiolitischronic cholecystitisbiliary tract infectionbacterial disease
Beyond the preview
Go deeper on 2021-002629-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002629-95.